Felbamate for Super-Refractory Status Epilepticus (PER726)

PER726 is an intravenous therapeutic drug candidate that seeks to treat patients experiencing status epilepticus that are unresponsive to current therapies.

This program is based on an IV drug delivery formulation of felbamate created by Perosphere. Felbamate is an approved, orally administered drug marketed as an anti-epileptic in the United States. Perosphere intends to pursue clinical development of felbamate for Super-Refractory Status Epilepticus (SRSE). Felbamate is highly insoluble in aqueous media and as a result cannot currently be administered intravenously, as is necessary for a neuroprotective indication. Perosphere has developed and applied for patents on a novel concentrated, formulation of felbamate suitable for IV administration.